Niagen Bioscience Stock
Niagen Bioscience Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert N. Fried
- Employees
- 117
- Market cap
- $197 M
- IPO
- 24/06/2015
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and…
Niagen Bioscience stock: price history
1D
-3.5%
1W
-7.4%
1M
-17.0%
6M
-48.6%
YTD
-60.8%
1Y
-66.4%
2Y
-30.1%
5Y
-60.8%
10Y
-10.8%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~25% weaker price swings than usual
Ask the agents about Niagen Bioscience
Analyst assessment of Niagen Bioscience
PRICE TARGET LOW
US$10.00
CONSENSUS
US$10.33
MEDIAN
US$10.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 11/05/2026
Niagen Bioscience stock metrics
P/E
12.82
P/B
2.39
EV/EBITDA
7.24
RETURN ON EQUITY
1.2%
NET MARGIN
3.2%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
65.7%
FLOAT SHARES
51,960,066
AVG. DAILY VOLUME (30D)
505,209
Insider transactions (SEC)
Fried Robert N
Pamir Ozan
Lopez Carlos Luis
Fried Robert N
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Niagen Bioscience stock
What does Niagen Bioscience do?
Niagen Bioscience Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert N. Fried, the company employs around 117 people.
The IPO was on 24/06/2015; the stock trades on NASDAQ under the ticker NAGE.
What do analysts say about Niagen Bioscience stock?
5 analysts rate the stock, the consensus is Buy (as of 11/05/2026).
The average price target is US$10.33, ranging from US$10.00 to US$11.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Niagen Bioscience report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -25% stronger than usual.
Does Niagen Bioscience pay a dividend?
No, Niagen Bioscience currently does not pay a dividend.
Which stocks are comparable to Niagen Bioscience?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Niagen Bioscience stock analyzed?
Clicking "Analyze stock" lets five strategies assess Niagen Bioscience against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.